Abstract
We undertook a point-of-care test (POCT) for hepatitis B core-related antigen (HBcrAg) on adults living with HBV in Kilifi, Kenya. A positive test identified all with hepatitis B viral load >200,000 IU/ml, who were HBeAg positive, and correlated with higher ALT (p = 0.03), raised APRI (p<0.001) and elastography scores (p = 0.03).
Competing Interest Statement
YS has received a research grant and honoraria for lectures from Gilead Sciences and research materials from Abbott Laboratories and Fujirebio Inc. PCM has previously received funding support for her group from GSK (outside the scope of this paper). YT has received scholarship donations from AbbVie GK and OTSUKA Pharmaceutical Co. and research funding from AbbVie GK, Fujirebio Inc, Sysmex Corp, GSK, Gilead Sciences and Janssen Pharmaceuticals. YT has also received lecture fees from AbbVie GK, Gilead Sciences, Chugai Pharmaceuticals, ASKA Pharmaceutical Holdings, OTSUKA Pharmaceutical Co., Takeda Pharmaceutical Co, GSK, AstraZeneca, Eisai and HU Frontier. No party had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Funding Statement
PCM receives core funding from the Francis Crick Institute (Ref: CC2223) and from University College London Hospitals NIHR Biomedical Research Centre (BRC). LD is funded by a Wellcome Doctoral Training Fellowship (grant number 225485/Z/22/Z) and by the Oxford Hospitals Charity Grant ref 1351. The study was partly funded by the JSPS KAKENHI (JP21K10416) and the Pasteur International Joint Research Unit. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Kenya Medical Research Institute Scientific Ethics Review Unit (SERU) and Oxford Tropical Research Ethics Committee of the University of Oxford both gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
For the purpose of Open Access, the author has applied a CC-BY public copyright license to any author accepted manuscript version arising from this submission. Data supporting the findings of this study will be publicly available on the acceptance of the manuscript for publication. This manuscript was written with the permission of Director KEMRI CGMRC.
